Title :

Venetoclax plus r- or g-chop in non-hodgkin lymphoma: results from the cavalli phase 1b trial

Author(s) :

Zelenetz, Andrew D. [Auteur]
Salles, Gilles [Auteur]
Mason, Kylie D. [Auteur]
Casulo, Carla [Auteur]
Le Gouill, Steven [Auteur]
Sehn, Laurie H. [Auteur]
Tilly, Herve [Auteur]
Cartron, Guillaume [Auteur]
Chamuleau, Martine E. D. [Auteur]
Goy, Andre [Auteur]
Tam, Constantine S. [Auteur]
Lugtenburg, Pieternella J. [Auteur]
Petrich, Adam M. [Auteur]
Sinha, Arijit [Auteur]
Samineni, Divya [Auteur]
Herter, Sylvia [Auteur]
Ingalla, Ellen [Auteur]
Szafer-Glusman, Edith [Auteur]
Klein, Christian [Auteur]
Sampath, Deepak [Auteur]
Kornacker, Martin [Auteur]
Mobasher, Mehrdad [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]

Journal title :

Blood

Abbreviated title :

Blood

Publication date :

2019-03-08

ISSN :

1528-0020

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Novel strategies, such as chemosensitization with targeted agents, that build on the success of standard immunochemotherapy show promise for the treatment of non-Hodgkin lymphoma (NHL). Here, we report a phase 1b study ...
Show more >Novel strategies, such as chemosensitization with targeted agents, that build on the success of standard immunochemotherapy show promise for the treatment of non-Hodgkin lymphoma (NHL). Here, we report a phase 1b study investigating dose escalation of the BCL2 inhibitor, venetoclax, in combination with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, vincristine, and prednisone (R-/G-CHOP) chemotherapy in B-cell NHL. Objectives included safety assessment and determination of a recommended phase 2 dose (RP2D). Fifty-six patients were enrolled, most with follicular lymphoma (43%) or diffuse large B-cell lymphoma (DLBCL; 32%). Dose-limiting toxicities were reported in 3/14 patients at the first venetoclax dose (200 mg/d), after which dosing was changed from daily to 10 days per cycle and escalated to 800 mg. A further reduction to 5 days per cycle occurred at the 800-mg dose level in the G-CHOP arm. Cytopenias were predominant among grade 3/4 events and reported at a higher rate than expected, particularly in the G-CHOP arm; however, safety was manageable. Overall response rates were 87.5% (R-CHOP and G-CHOP combinations); complete response (CR) rates were 79.2% and 78.1%, respectively. Most double-expressor (BCL2++Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Research team(s) :

Modélisation biopharmaceutique et pharmacocinétique

Submission date :

2019-12-16T14:06:39Z